The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.
October - December 2025 for the Group
Net sales amounted to TSEK 2,459 (1,221)
Result before tax amounted to TSEK -2,623 (-2,829)
Result per share was SEK -0.12 (-0.19)
Equity ratio amounted to 91% (69%) on December 31, 2025
Full year 2025 for the Group
Net sales amounted to TSEK 6,853 (4,737)
Result before tax amounted to TSEK -12,145 (-15,078)
Result per share was SEK -0.64 (-1.01)
Equity ratio amounted to 91% (69%) on December 31, 2025
October - December 2025 for the Parent company
Net sales amounted to TSEK 2,416 (1,252)
Result before tax amounted to TSEK -4,040 (-4,769)
Result per share was SEK -0.19 (-0.32)
Equity ratio amounted to 92% (69%) on December 31, 2025
Full year 2025 for the Parent company
Net sales amounted to TSEK 6,799 (4,760)
Result before tax amounted to TSEK -13,332 (-15,848)
Result per share was SEK -0.71 (-1.06)
Equity ratio amounted to 92% (69%) on December 31, 2025
Significant events during the fourth quarter
* On November 19, AcouSort announced it had signed a technology evaluation agreement with the Danish diagnostics company SeeQ Diagnostics concerning the evaluation of AcouSort's blood/plasma separation technology for automatically preparing blood samples for the SepSeeQ assay.
* On December 15, AcouSort announced that Stefan Blomsterberg was elected new Chairman of the Board of AcouSort, effective January 1, 2026.
* On December 19, AcouSort announced it has entered a collaboration with MFX, a UK-based developer of next-generation scalable bioreactor platforms, to evaluate if AcouSort's technology can be paired with MFX's innovative platform and workflow to streamline cell therapy manufacturing.
* On December 29, AcouSort announced it has signed three separate contracts around the AcouWash benchtop system, including an order from a research group at the University of Wisconsin-Madison.
Significant events after the end of the period
* On January 23, AcouSort AB announced it has initiated a feasibility project with a large international manufacturing company aiming at investigating the applicability of AcouSort's technology for removing particles in different steps of production workflows.
CEO statement Q4 2025
Strong finish to an intensive year
AcouSort is ending 2025 and entering 2026 with strong commercial momentum, expanding partnerships, and a validated technology platform that solves critical automation challenges in diagnostics and cell therapy. With growing OEM interest, strengthened financials, and increasing scientific recognition, the company is now positioned to scale from technology validation into broader commercial adoption. Total income in the quarter amounted to MSEK 2.8 (3.2), of which net revenues amounted to MSEK 2.5 (1.2). For the full year, total income amounted to MSEK 10.4 (10.0), including MSEK 6.9 (4.7) in net revenues.
STRONG MOMENTUM
AcouSort net revenues increased in 2025 from SEK 4.7 to SEK 6.9 representing an increase of 44.7%. This rise came from an increase in license fees of 45.4% and product sales and services of 42.4%.
AcouSort is having a strong momentum, a scalable business model, and rapidly expanding commercial traction. Our acoustic-based sample preparation technology addresses one of the most critical bottlenecks in diagnostics, cell therapy and lab automation: Efficient, automated, and cost-reducing processing of biological samples.
CLEAR STRATEGY - OEM DRIVEN GROWTH
Our long-term strategy is to become the embedded technology provider for next-generation diagnostic systems, cell therapy workflows, and automated lab platforms. Through OEM partnerships, AcouSort can scale rapidly with minimal commercial overhead and achieve high-margin recurring revenue streams.
STRONG COMMERCIAL TRACTION
2025 brought several strategically important collaborations. In the fourth quarter alone, we signed several important agreements that fit perfectly with our strategy:
- Technology integration project with SEEQ Diagnostics involving collaboration with a major international lab automation player.
- Technology evaluation and integration project with MFX, validating our platform for their innovative and scalable CAR-T manufacturing solution.
- Expanded global footprint of the AcouWash system through new orders and leases across the US, Europe and Asia.
- A new feasibility project with a global industrial manufacturer is a potential entry point into high-volume production environments.
These projects not only generate near-term revenue; they also support our ambition to become the new gold standard for biological sample preparation or they represent pipelines toward long-term OEM agreements.
COMPELLING MARKET OPPORTUNITY
Cell therapy alone represents a rapidly accelerating multi-billion-dollar market. Current therapies focus on blood cancers, yet only ~2% of eligible patients receive treatment due to cost and manufacturing constraints.
AcouSort's technology has the potential to enable:
- Lowering cost per dose;
- Reducing labor and time requirements; and
- Supporting scalable and sustainable production
We estimate an addressable market of USD 300 million by 2030 in blood cancers alone with substantial upside if cell therapies expand into solid tumors.
GROWING SCIENTIFIC VALIDATION
AcouSort's technology was highlighted at major industry conferences and further validated through a new NIH/NCI scientific publication demonstrating successful use of AcouWash in advanced radiolabeling workflows thus validating AcouSort's technology for advanced radiotherapy treatment. This strengthens our position as a trusted innovation partner for leading research institutions. The recent placement of an AcouWash system at University of Wisconsin, Madison, WI, is directly triggered by the NIC/NCI publications.
STRENGTHENED FINANCIAL FOUNDATION
A successful rights issue of SEK 24.9 million in 2025, combined with known income such as royalties and public funding, as well as projected product and project revenues in 2026 secures funding for our critical OEM-driven development program and positions the company into 2027.
At the same time, we are now actively engaging with long-term, value-adding investors to support AcouSort through the next stages of commercialization.
2026 - A PIVOTAL YEAR
With a strong pipeline of feasibility studies, expanding partnerships, and planned additional product offerings, AcouSort is now positioned to transition from technology validation to commercial scale-up.
Our goal for 2026/27 is clear:
Convert multiple exploratory collaborations into long-term OEM agreements that unlock scalable, recurring revenue.
I look forward to keeping you updated around upcoming milestones and the progress of our exciting program.
Torsten Freltoft
CEO
The report is attached below and can also be found at https://acousort.com/investor/financial-reports/
FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com
ABOUT ACOUSORT
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing - so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Tapper Partners AB.
